GH - Guardant Health Inc Stock Price, Fair Value and News

33.02USD+1.09 (+3.41%)Market Closed

Market Summary

USD33.02+1.09

Market Closed

3.41%

GH Stock Price

View Fullscreen

GH RSI Chart

GH Valuation

Market Cap

4.0B

Price/Earnings (Trailing)

-8.77

Price/Sales (Trailing)

6.69

EV/EBITDA

-10.02

Price/Free Cashflow

-13.44

GH Price/Sales (Trailing)

GH Profitability

EBT Margin

-76.20%

Return on Equity

-674.97%

Return on Assets

-27.04%

Free Cashflow Yield

-7.44%

GH Fundamentals

GH Revenue

Revenue (TTM)

603.7M

Rev. Growth (Yr)

30.9%

Rev. Growth (Qtr)

8.67%

GH Earnings

Earnings (TTM)

-460.9M

Earnings Growth (Yr)

13.89%

Earnings Growth (Qtr)

38.52%

Breaking Down GH Revenue

Last 7 days

7.4%

Last 30 days

12.4%

Last 90 days

90.3%

Trailing 12 Months

-11.7%

How does GH drawdown profile look like?

GH Financial Health

Current Ratio

5.95

Debt/Equity

16.7

Debt/Cashflow

-0.25

GH Investor Care

Shares Dilution (1Y)

19.08%

Diluted EPS (TTM)

-3.94

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	603.7M	0	0	0
2023	482.2M	510.2M	535.8M	563.9M
2022	391.1M	408.1M	430.8M	449.5M
2021	297.9M	323.7M	343.9M	373.7M
2020	245.2M	257.6M	271.3M	286.7M
2019	110.6M	145.2M	184.4M	214.4M
2018	60.0M	70.2M	80.4M	90.6M
2017	0	0	37.5M	49.8M
2016	0	0	0	25.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

CEO	Dr. Helmy Eltoukhy Ph.D.
WEBSITE	https://guardanthealth.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	1793

Guardant Health Inc Frequently Asked Questions

What is the ticker symbol for Guardant Health Inc? What does GH stand for in stocks?

GH is the stock ticker symbol of Guardant Health Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Guardant Health Inc (GH)?

As of Fri Jul 26 2024, market cap of Guardant Health Inc is 4.04 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GH stock?

You can check GH's fair value in chart for subscribers.

Is Guardant Health Inc a good stock to buy?

The fair value guage provides a quick view whether GH is over valued or under valued. Whether Guardant Health Inc is cheap or expensive depends on the assumptions which impact Guardant Health Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GH.

What is Guardant Health Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, GH's PE ratio (Price to Earnings) is -8.77 and Price to Sales (PS) ratio is 6.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GH PE ratio will change depending on the future growth rate expectations of investors.